Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts give Amylyx a consensus "Moderate Buy" rating (14 analysts: 1 sell, 2 hold, 9 buy, 2 strong buy) with an average 12‑month price target of about $21.56.
• Institutional investors own 95.84% of the company; Millennium Management notably increased its stake by 418.6% to roughly 3.08 million shares (≈$10.91M) and Goldman Sachs also added to its position.
• Amylyx shares recently traded around $16.46 with a market cap of $1.83B and a 52‑week range of $4.20–$18.60; the company posted a slight quarterly EPS beat (loss of $0.30 vs. $0.31 expected) and analysts expect ~‑1.39 EPS for the year.

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fourteen analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, nine have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $21.5556.

AMLX has been the subject of several analyst reports. Mizuho upped their target price on Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the company an "outperform" rating in a research note on Tuesday, April 28th. HC Wainwright reiterated a "buy" rating and issued a $34.00 target price on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 25th. Wall Street Zen upgraded Amylyx Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, March 7th. Stifel Nicolaus initiated coverage on Amylyx Pharmaceuticals in a research note on Tuesday, March 3rd. They issued a "buy" rating and a $21.00 target price for the company. Finally, Bank of America upped their target price on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a "buy" rating in a research note on Friday, February 20th.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in AMLX. Millennium Management LLC grew its position in Amylyx Pharmaceuticals by 418.6% during the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company's stock valued at $10,910,000 after acquiring an additional 2,487,617 shares during the period. Goldman Sachs Group Inc. grew its position in Amylyx Pharmaceuticals by 7.7% during the first quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company's stock valued at $7,090,000 after acquiring an additional 143,065 shares during the period. JPMorgan Chase & Co. grew its position in Amylyx Pharmaceuticals by 62.7% during the second quarter. JPMorgan Chase & Co. now owns 87,989 shares of the company's stock valued at $564,000 after acquiring an additional 33,920 shares during the period. Legal & General Group Plc purchased a new stake in Amylyx Pharmaceuticals during the second quarter valued at about $47,000. Finally, Rhumbline Advisers purchased a new stake in Amylyx Pharmaceuticals during the second quarter valued at about $645,000. Hedge funds and other institutional investors own 95.84% of the company's stock.

Amylyx Pharmaceuticals Trading Up 2.8%

Amylyx Pharmaceuticals stock opened at $16.46 on Tuesday. The firm has a market capitalization of $1.83 billion, a P/E ratio of -10.62 and a beta of -0.11. The stock has a fifty day moving average price of $15.26 and a 200 day moving average price of $14.25. Amylyx Pharmaceuticals has a 52 week low of $4.20 and a 52 week high of $18.60.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its earnings results on Tuesday, March 3rd. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.01. As a group, equities analysts predict that Amylyx Pharmaceuticals will post -1.39 EPS for the current year.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company's lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.